Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kyverna Therapeutics, Inc. - Common Stock (NQ:KYTX)

7.900 +0.220 (+2.86%)
Streaming Delayed Price Updated: 11:27 AM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kyverna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Kyverna Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Impacted Investors Are Invited To Contact The Schall Law Firm
Via ACCESSWIRE
News headline image
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX
Via ACCESSWIRE
News headline image
Kyverna Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the KYTX Class Action Lawsuit
From Robbins LLP
Via GlobeNewswire
News headline image
Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX
Via ACCESSWIRE
News headline image
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
Via ACCESSWIRE
News headline image
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
Via ACCESSWIRE
News headline image
Class Action Filed Against Kyverna Therapeutics, Inc. (KYTX) - February 7, 2025 Deadline to Join – Contact Levi & Korsinsky
Via ACCESSWIRE
News headline image
Shareholders of Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
Via ACCESSWIRE
News headline image
The Schall Law Firm Encourages Stockholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc
Via ACCESSWIRE
News headline image
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
From DiCello Levitt LLP
Via GlobeNewswire
News headline image
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
Via ACCESSWIRE
News headline image
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
Via ACCESSWIRE
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
Via ACCESSWIRE
News headline image
KYTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
KYVERNA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kyverna Therapeutics, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
KYVERNA THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Rosen Law Firm Urges Kyverna Therapeutics, Inc. (NASDAQ: KYTX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) INVESTOR ALERT: Investors With Large Losses in Kyverna Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Kyverna Therapeutics, Inc. (NASDAQ: KYTX)
From Scott+Scott Attorneys at Law LLP
Via Business Wire
News headline image
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases ↗
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads. 
Via Investor's Business Daily
News headline image
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday ↗
 
Via Benzinga
News headline image
KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q2 2024 ↗
KYTX stock results show that Kyverna Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.